Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10

Javier F. Torres-Roca, Michelle DeSilvio, Linda B. Mora, Li Yan Khor, Elizabeth Hammond, Nazeel Ahmad, Richard Jove, Jeffrey Forman, R. Jeffrey Lee, Howard Sandler, Alan Pollack

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: STAT3 participates in the regulation of cellular growth, survival, and oncogenesis. We evaluated the association between activated STAT3 expression and overall survival, disease-specific survival, distant metastasis, and local progression in a cohort of patients treated with either radiotherapy alone or radiotherapy plus short-term androgen blockade. Methods: A total of 456 assessable patients were included in the Radiation Therapy Oncology Group 86-10 trial. Of these, 62 patients had sufficient tissue for the analysis of STAT3 expression by immunohistochemistry. Nuclear staining was quantified by an image analysis system. Results: No significant difference was found in the distribution of clinical characteristics and assigned treatment between the patients available for STAT3 analysis (STAT3 cohort) and the others in the Radiation Therapy Oncology Group 86-10 trial (n = 394). Activated STAT3 correlated inversely with the development of distant metastasis (risk ratio [RR] = 0.81, P = 0.04) but not with overall survival, cause-specific survival, or local progression. Similar results were obtained when the data were dichotomized (ACIS index greater than 29%, RR = 0.41, P = 0.07). On multivariate analysis, activated STAT3 (continuous variable) was an independent predictor of distant metastasis (RR = 0.79, P = 0.04). Conclusions: Activated STAT3 was inversely related to the development of distant metastasis in prostate cancer. This marker should be evaluated further in a larger cohort of patients.

Original languageEnglish
Pages (from-to)505-509
Number of pages5
JournalUrology
Volume69
Issue number3
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Radiation Oncology
Prostatic Neoplasms
Radiotherapy
Neoplasm Metastasis
Survival
Odds Ratio
Hospital Distribution Systems
Androgens
Carcinogenesis
Cohort Studies
Multivariate Analysis
Immunohistochemistry
Staining and Labeling
Growth

ASJC Scopus subject areas

  • Urology

Cite this

Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer : A Secondary Analysis of Radiation Therapy Oncology Group 86-10. / Torres-Roca, Javier F.; DeSilvio, Michelle; Mora, Linda B.; Khor, Li Yan; Hammond, Elizabeth; Ahmad, Nazeel; Jove, Richard; Forman, Jeffrey; Lee, R. Jeffrey; Sandler, Howard; Pollack, Alan.

In: Urology, Vol. 69, No. 3, 01.03.2007, p. 505-509.

Research output: Contribution to journalArticle

Torres-Roca, JF, DeSilvio, M, Mora, LB, Khor, LY, Hammond, E, Ahmad, N, Jove, R, Forman, J, Lee, RJ, Sandler, H & Pollack, A 2007, 'Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10', Urology, vol. 69, no. 3, pp. 505-509. https://doi.org/10.1016/j.urology.2006.11.006
Torres-Roca, Javier F. ; DeSilvio, Michelle ; Mora, Linda B. ; Khor, Li Yan ; Hammond, Elizabeth ; Ahmad, Nazeel ; Jove, Richard ; Forman, Jeffrey ; Lee, R. Jeffrey ; Sandler, Howard ; Pollack, Alan. / Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer : A Secondary Analysis of Radiation Therapy Oncology Group 86-10. In: Urology. 2007 ; Vol. 69, No. 3. pp. 505-509.
@article{6a22b5737649487abe2d6069e8176cfa,
title = "Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer: A Secondary Analysis of Radiation Therapy Oncology Group 86-10",
abstract = "Objective: STAT3 participates in the regulation of cellular growth, survival, and oncogenesis. We evaluated the association between activated STAT3 expression and overall survival, disease-specific survival, distant metastasis, and local progression in a cohort of patients treated with either radiotherapy alone or radiotherapy plus short-term androgen blockade. Methods: A total of 456 assessable patients were included in the Radiation Therapy Oncology Group 86-10 trial. Of these, 62 patients had sufficient tissue for the analysis of STAT3 expression by immunohistochemistry. Nuclear staining was quantified by an image analysis system. Results: No significant difference was found in the distribution of clinical characteristics and assigned treatment between the patients available for STAT3 analysis (STAT3 cohort) and the others in the Radiation Therapy Oncology Group 86-10 trial (n = 394). Activated STAT3 correlated inversely with the development of distant metastasis (risk ratio [RR] = 0.81, P = 0.04) but not with overall survival, cause-specific survival, or local progression. Similar results were obtained when the data were dichotomized (ACIS index greater than 29{\%}, RR = 0.41, P = 0.07). On multivariate analysis, activated STAT3 (continuous variable) was an independent predictor of distant metastasis (RR = 0.79, P = 0.04). Conclusions: Activated STAT3 was inversely related to the development of distant metastasis in prostate cancer. This marker should be evaluated further in a larger cohort of patients.",
author = "Torres-Roca, {Javier F.} and Michelle DeSilvio and Mora, {Linda B.} and Khor, {Li Yan} and Elizabeth Hammond and Nazeel Ahmad and Richard Jove and Jeffrey Forman and Lee, {R. Jeffrey} and Howard Sandler and Alan Pollack",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.urology.2006.11.006",
language = "English",
volume = "69",
pages = "505--509",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Activated STAT3 as a Correlate of Distant Metastasis in Prostate Cancer

T2 - A Secondary Analysis of Radiation Therapy Oncology Group 86-10

AU - Torres-Roca, Javier F.

AU - DeSilvio, Michelle

AU - Mora, Linda B.

AU - Khor, Li Yan

AU - Hammond, Elizabeth

AU - Ahmad, Nazeel

AU - Jove, Richard

AU - Forman, Jeffrey

AU - Lee, R. Jeffrey

AU - Sandler, Howard

AU - Pollack, Alan

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Objective: STAT3 participates in the regulation of cellular growth, survival, and oncogenesis. We evaluated the association between activated STAT3 expression and overall survival, disease-specific survival, distant metastasis, and local progression in a cohort of patients treated with either radiotherapy alone or radiotherapy plus short-term androgen blockade. Methods: A total of 456 assessable patients were included in the Radiation Therapy Oncology Group 86-10 trial. Of these, 62 patients had sufficient tissue for the analysis of STAT3 expression by immunohistochemistry. Nuclear staining was quantified by an image analysis system. Results: No significant difference was found in the distribution of clinical characteristics and assigned treatment between the patients available for STAT3 analysis (STAT3 cohort) and the others in the Radiation Therapy Oncology Group 86-10 trial (n = 394). Activated STAT3 correlated inversely with the development of distant metastasis (risk ratio [RR] = 0.81, P = 0.04) but not with overall survival, cause-specific survival, or local progression. Similar results were obtained when the data were dichotomized (ACIS index greater than 29%, RR = 0.41, P = 0.07). On multivariate analysis, activated STAT3 (continuous variable) was an independent predictor of distant metastasis (RR = 0.79, P = 0.04). Conclusions: Activated STAT3 was inversely related to the development of distant metastasis in prostate cancer. This marker should be evaluated further in a larger cohort of patients.

AB - Objective: STAT3 participates in the regulation of cellular growth, survival, and oncogenesis. We evaluated the association between activated STAT3 expression and overall survival, disease-specific survival, distant metastasis, and local progression in a cohort of patients treated with either radiotherapy alone or radiotherapy plus short-term androgen blockade. Methods: A total of 456 assessable patients were included in the Radiation Therapy Oncology Group 86-10 trial. Of these, 62 patients had sufficient tissue for the analysis of STAT3 expression by immunohistochemistry. Nuclear staining was quantified by an image analysis system. Results: No significant difference was found in the distribution of clinical characteristics and assigned treatment between the patients available for STAT3 analysis (STAT3 cohort) and the others in the Radiation Therapy Oncology Group 86-10 trial (n = 394). Activated STAT3 correlated inversely with the development of distant metastasis (risk ratio [RR] = 0.81, P = 0.04) but not with overall survival, cause-specific survival, or local progression. Similar results were obtained when the data were dichotomized (ACIS index greater than 29%, RR = 0.41, P = 0.07). On multivariate analysis, activated STAT3 (continuous variable) was an independent predictor of distant metastasis (RR = 0.79, P = 0.04). Conclusions: Activated STAT3 was inversely related to the development of distant metastasis in prostate cancer. This marker should be evaluated further in a larger cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=33947308781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947308781&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2006.11.006

DO - 10.1016/j.urology.2006.11.006

M3 - Article

C2 - 17382154

AN - SCOPUS:33947308781

VL - 69

SP - 505

EP - 509

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -